| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/12/2002 | US20020127248 Using rapamycin compound for therapy and prophylaxis of neointimal proliferation and thickening |
| 09/12/2002 | US20020127244 Fractionating a mixture of polyethylene glycol(PEG)-protein adducts comprising partitioning the PEG/protein adducts in a PEG-containing aqueous biphasic system |
| 09/12/2002 | US20020127243 Administering dietary supplement comprising soybean, mushroom and mung bean or extracts to ameliorate at least one effect of malignancy or viral infection |
| 09/12/2002 | US20020127238 Utilizing a modified HIV-1 envelope protein or fragment or DNA encoding a modified HIV-1 envelope protein or fragment, wherein modified protein having a HIV-1 envelope protein V2 region deletion |
| 09/12/2002 | US20020127232 Activating alpha 2-macroglobulin by incubation with a nucleophilic compound to form nucleophile-activated alpha 2-macroglobulin, removing excess of nucleophilic compound, incubating activated alpha-2 macroglobulin with biomolecule |
| 09/12/2002 | US20020127230 Transcutaneous photodynamic therapy ("PDT") of a target tissue |
| 09/12/2002 | US20020127228 Measuring the ability to induce apoptosis of cells with the expression of prostaglandin transproter; antitumor, anticancer agent |
| 09/12/2002 | US20020127223 Binding antibodies or antiboy-comparable with affinity for body cells not meant to be affected by chemotherapeutical drug directly to an antidote or to carriers such as proteins, or microbody carriers such as liposomes, erythroctes |
| 09/12/2002 | US20020127217 A polynucleotides which identify and encode Phosphatidylinositol 4,5-bisphosphate 5-phosphatase (polypeptide) |
| 09/12/2002 | US20020127215 Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections |
| 09/12/2002 | US20020127213 Administering to patient a therapeutically effective amount of both an N-alkyl derivative of deoxynojirimycin and a glucocerebrosidase enzyme to alleviate or inhibit glycolipid storage disease; Gaucher's disease |
| 09/12/2002 | US20020127211 Increasing or facilitating absorption of minerals from diet using enteral nutritional composition which includes lactobacilli |
| 09/12/2002 | US20020127209 Tripeptide of intracellular tyrosine-based activation motifs (ITAM) mediates trafficking of targets phagocytosed via Fc gamma RIIA to the lysosomal compartment |
| 09/12/2002 | US20020127204 Improvements in or relating to protection against intracellular infection |
| 09/12/2002 | US20020127203 Polypeptide having phenylacetyl-coenzyme a ligase activity which has been isolated from culture; for production of penicillin |
| 09/12/2002 | US20020127197 Methods for treating urinary incontinence in mammals |
| 09/12/2002 | US20020127188 Composition for pulmonary administration comprising a drug and a hydrophobic amino acid |
| 09/12/2002 | US20020127187 Administering aerosol particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension to treat allergic rhinitis and asthma |
| 09/12/2002 | US20020127185 Pharmaceutical aerosol formulations containing fluoroalkanes and budesonide |
| 09/12/2002 | US20020127184 Effervescent tablet compositions |
| 09/12/2002 | DE10111877A1 Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate New imidazolidine derivatives, their preparation, their use and pharmaceutical compositions containing them |
| 09/12/2002 | DE10111058A1 Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und NK¶1¶-Rezeptor-Antagonisten New pharmaceutical compositions based on anticholinergics and NK¶1¶ receptor antagonists |
| 09/12/2002 | DE10111053A1 Wirkstoffkombinationen aus alpha-Liponsäure und Biochinonen Active compound combinations of alpha-lipoic acid and bioquinones |
| 09/12/2002 | DE10111046A1 Cosmetic or dermatological preparations for treating or preventing pigmentation disorders, e.g. freckles or liver spots, containing active agent combination of alpha-lipoic acid and UV-A or UV-B absorber |
| 09/12/2002 | DE10111045A1 Cosmetic or dermatological preparations, useful e.g. for treating inflammatory skin disorders, pigmentation disorders or aging, containing combination of alpha-lipoic acid and (iso)flavone, flavanone or flavonoid |
| 09/12/2002 | DE10111040A1 Use of combinations of alpha-lipoic acid and ultraviolet absorbers for treating inflammatory skin disorders or protecting sensitive dry skin |
| 09/12/2002 | DE10111039A1 Verwendung von Wirkstoffkombinationen aus alpha-Liponsäure und dermatologisch verträglichen Substanzen, die Lichtabsorption im UV-A-Bereich und/oder UV-B-Bereich zeigen, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe der Symptome der intrinsischen und/oder extrinsischen Hautalterung sowie zur Behandlung und Prophylaxe der schädlichen Auwirkungen ultravioletter Strahlung auf die Haut Use of active compound combinations of alpha-lipoic acid and dermatologically acceptable substances which light absorption in the UV-A region and / or UV-B range show, for the preparation of cosmetic or dermatological preparations for the treatment and / or prophylaxis of the symptoms of intrinsic and / or extrinsic skin aging and for the treatment and prophylaxis of the harmful effects of becoming ultraviolet radiation on the skin |
| 09/12/2002 | DE10110772A1 Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren New pharmaceutical compositions based on anticholinergics and PDE IV inhibitors |
| 09/12/2002 | DE10110750A1 Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften Novel Aminodicarbonsäurederivate with pharmaceutical properties |
| 09/12/2002 | DE10110749A1 Substituierte Aminodicarbonsäurederivate Substituted Aminodicarbonsäurederivate |
| 09/12/2002 | DE10110747A1 Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use |
| 09/12/2002 | DE10110418A1 Melatonin-Vitamin-A-Präparate Melatonin and vitamin A supplements |
| 09/12/2002 | DE10109855A1 Polypeptide eines p53-Protein-spezifischen murinen alpha/beta T-Zell Rezeptors, diese kodierende Nukleinsäuren und deren Verwendung Polypeptide of a p53 protein specific murine alpha / beta T-cell receptor nucleic acids encoding these, and their use |
| 09/12/2002 | DE10109854A1 Polypeptide eines hdm2-Protein spezifischen murinen alpha/beta T-Zell Rezeptors, diese kodierende Nukleinsäuren und deren Verwendung Polypeptides of hdm2 protein specific murine alpha / beta T-cell receptor nucleic acids encoding these, and their use |
| 09/12/2002 | DE10109813A1 Tumor-Peptidantigen aus humanem mdm2 Proto-Onkogen Tumor antigen peptide from human MDM2 proto-oncogene |
| 09/12/2002 | DE10109166A1 Avilamycin-Derivate Avilamycin derivatives |
| 09/12/2002 | DE10108851A1 Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten Use of 5'-substituted nucleosides and / or their prodrugs for the resistance-free therapy of infectious diseases |
| 09/12/2002 | DE10107261A1 Pharmazeutische Zusammensetzung Pharmaceutical composition |
| 09/12/2002 | CA2788498A1 Polymorphic and other crystalline forms of cis-ftc |
| 09/12/2002 | CA2445308A1 Progestin co-micronized with a surfactant, pharmaceutical composition comprising same, methods for making same and uses thereof |
| 09/12/2002 | CA2445018A1 Tumour peptide antigen produced from human mdm2 proto-oncogene |
| 09/12/2002 | CA2445013A1 Polypeptides of an hdm2 protein-specific murine alpha/beta t-cell receptor, nucleic acids encoding these and their use |
| 09/12/2002 | CA2445004A1 Polypeptides of a p53 protein-specific murine alpha/beta t-cell receptor, nucleic acids encoding these and their use |
| 09/12/2002 | CA2442396A1 Method and formula for anti-tumor and anti-matastatic effect |
| 09/12/2002 | CA2442260A1 Use of one or more shogaol(s) as an aphrodisiac |
| 09/12/2002 | CA2440809A1 Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors |
| 09/12/2002 | CA2440803A1 Modulators of chemokine receptor activity |
| 09/12/2002 | CA2440642A1 Dimeric isoflavones |
| 09/12/2002 | CA2440161A1 Inhibitor of monoamine uptake |
| 09/12/2002 | CA2440141A1 Compounds and methods for the treatment of urogenital disorders |
| 09/12/2002 | CA2440100A1 New use |
| 09/12/2002 | CA2440070A1 Pharmaceutical composition made of cannabis extracts |
| 09/12/2002 | CA2440069A1 Taste masked pharmaceutical compositions |
| 09/12/2002 | CA2440038A1 Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and use thereof |
| 09/12/2002 | CA2439945A1 Novel halogen-substituted aminodicarboxylic acid derivatives |
| 09/12/2002 | CA2439939A1 Novel aminodicarboxylic acid derivatives |
| 09/12/2002 | CA2439933A1 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 09/12/2002 | CA2439917A1 Compositions having improved bioavailability of eletriptan |
| 09/12/2002 | CA2439915A1 New pharmaceutical compositions based on anticholinergics and nk1-receptor antagonists |
| 09/12/2002 | CA2439859A1 N-but-3-enyl norbuprenorphine and its use as analgesic |
| 09/12/2002 | CA2439852A1 Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists |
| 09/12/2002 | CA2439849A1 Antagonists of mcp-1 function and methods of use thereof |
| 09/12/2002 | CA2439836A1 Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides |
| 09/12/2002 | CA2439827A1 Peptide deformylase inhibitors |
| 09/12/2002 | CA2439820A1 Benzophenones as inhibitors of reverse transcriptase |
| 09/12/2002 | CA2439793A1 Composition for the treatment of diabetes mellitus |
| 09/12/2002 | CA2439759A1 Substituted amino dicarboxylic acid derivatives |
| 09/12/2002 | CA2439691A1 Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
| 09/12/2002 | CA2439687A1 Use of certain steroids for treatment of blood cell deficiencies |
| 09/12/2002 | CA2439666A1 Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity |
| 09/12/2002 | CA2439647A1 Side-chain-halogenated aminodicarboxylic acid derivatives as medicaments for treatment of cardiovascular disorders |
| 09/12/2002 | CA2439644A1 Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours |
| 09/12/2002 | CA2439581A1 Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders |
| 09/12/2002 | CA2439489A1 Preparation of warfarin sodium from warfarin sodium-2-propanol clathrate by solvent expulsion |
| 09/12/2002 | CA2439460A1 A process for the manufacture of pharmaceutical tablets containing paroxetine hydrochloride anhydrate |
| 09/12/2002 | CA2439413A1 Virucidal compositions |
| 09/12/2002 | CA2439293A1 Enteral formulation |
| 09/12/2002 | CA2439205A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439203A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439200A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439197A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439196A1 Nuclear hormone receptor ligand binding domains |
| 09/12/2002 | CA2439195A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439192A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2438849A1 Compounds and compositions for delivering active agents |
| 09/12/2002 | CA2438847A1 Amphotericin b aqueous composition |
| 09/12/2002 | CA2438829A1 Methods for preparing new taxoids and pharmaceutical compositions containing them |
| 09/12/2002 | CA2438815A1 Novel 2,5-diazabicyclo[2.2.1]heptane derivatives |
| 09/12/2002 | CA2438737A1 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as ip antagonists |
| 09/12/2002 | CA2437594A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 09/12/2002 | CA2437592A1 Malic acid addition salts of terbinafine |
| 09/12/2002 | CA2434601A1 Methods for specifically inhibiting histone deacetylase-4 |
| 09/12/2002 | CA2434184A1 Bisaryl derivatives having fsh receptor modulatory activity |
| 09/12/2002 | CA2434066A1 Chromane derivatives, process for their preparation and their use as antitumor agents |
| 09/12/2002 | CA2433467A1 Substituted quinolinecarboxamides as antiviral agents |
| 09/12/2002 | CA2432280A1 Novel glutamate receptor modulatory proteins and nucleic acid molecules and uses therefor |
| 09/12/2002 | CA2431549A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| 09/12/2002 | CA2340556A1 Use of zinc tranexamate in the treatment of diabetes |
| 09/11/2002 | EP1238978A2 Intermediates for the synthesis of radiolabelled tropanes |
| 09/11/2002 | EP1238974A1 Heterocycle derivatives and drugs |